70 related articles for article (PubMed ID: 11122108)
1. Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia.
Chen X; Regn S; Raffegerst S; Kolb HJ; Roskrow M
Br J Haematol; 2000 Nov; 111(2):596-607. PubMed ID: 11122108
[TBL] [Abstract][Full Text] [Related]
2. Rapid generation of antigen-presenting cells from leukaemic blasts in acute myeloid leukaemia.
Westers TM; Stam AG; Scheper RJ; Regelink JC; Nieuwint AW; Schuurhuis GJ; van de Loosdrecht AA; Ossenkoppele GJ
Cancer Immunol Immunother; 2003 Jan; 52(1):17-27. PubMed ID: 12536236
[TBL] [Abstract][Full Text] [Related]
3. Immunostimulatory properties of human dendritic cells generated using IFN-beta associated either with IL-3 or GM-CSF.
Mazouz N; Detournay O; Buelens C; Renneson J; Trakatelli M; Lambermont M; Goldman M; Toungouz M
Cancer Immunol Immunother; 2005 Oct; 54(10):1010-7. PubMed ID: 15864589
[TBL] [Abstract][Full Text] [Related]
4. Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study.
Westermann J; Reich G; Kopp J; Haus U; Dörken B; Pezzutto A
Cancer Immunol Immunother; 2001 Jan; 49(11):613-20. PubMed ID: 11225992
[TBL] [Abstract][Full Text] [Related]
5. In situ recruitment of antigen-presenting cells by intratumoral GM-CSF gene delivery.
Pan PY; Li Y; Li Q; Gu P; Martinet O; Thung S; Chen SH
Cancer Immunol Immunother; 2004 Jan; 53(1):17-25. PubMed ID: 12955480
[TBL] [Abstract][Full Text] [Related]
6. CD80 (B7-1) expression on human acute myeloid leukaemic cells cultured with GM-CSF, IL-3 and IL-6.
Hicks C; Keoshkerian E; Gaudry L; Lindeman R
Cancer Immunol Immunother; 2001 Jun; 50(4):173-80. PubMed ID: 11459169
[TBL] [Abstract][Full Text] [Related]
7. Human T lymphocyte activation in the presence of acute myelogenous leukaemia blasts; studies of normal polyclonal T cells and T lymphocyte clones derived early after allogenic bone marrow transplantation.
Bruserud O; Pawelec G
Cancer Immunol Immunother; 1996 Mar; 42(3):133-40. PubMed ID: 8640841
[TBL] [Abstract][Full Text] [Related]
8. Generation of dendritic cells from peripheral blood of patients at different stages of chronic myeloid leukemia.
Zheng C; Pisa P; Stromberg O; Blennow E; Hansson M
Med Oncol; 2000 Nov; 17(4):270-8. PubMed ID: 11114705
[TBL] [Abstract][Full Text] [Related]
9. Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation.
Houtenbos I; Westers TM; Stam AG; de Gruijl TD; Scheper RJ; Ossenkoppele GJ; van de Loosdrecht AA
Cancer Immunol Immunother; 2003 Jul; 52(7):455-62. PubMed ID: 12690520
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients.
Pilla L; Patuzzo R; Rivoltini L; Maio M; Pennacchioli E; Lamaj E; Maurichi A; Massarut S; Marchianò A; Santantonio C; Tosi D; Arienti F; Cova A; Sovena G; Piris A; Nonaka D; Bersani I; Di Florio A; Luigi M; Srivastava PK; Hoos A; Santinami M; Parmiani G
Cancer Immunol Immunother; 2006 Aug; 55(8):958-68. PubMed ID: 16215718
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic and noncytotoxic mechanisms involved in the in vitro anti-leukaemia effects of T cell clones established from a chronic myelogenous leukaemia patient during treatment in vivo with interferon alpha.
Pawelec G; Reutter M; Owsianowsky M; Rehbein A; Busch FW
Cancer Immunol Immunother; 1991; 33(1):54-60. PubMed ID: 1902397
[TBL] [Abstract][Full Text] [Related]
12. Generation of cytotoxic T lymphocytes from peripheral blood of leukaemic patients.
Nouri AM; Dorey E; Davis CL; Rohatiner A; Lister TA; Oliver RT
Cancer Immunol Immunother; 1993 Jul; 37(1):47-53. PubMed ID: 8513452
[TBL] [Abstract][Full Text] [Related]
13. Generation of a novel CD30
Higashioka K; Kikushige Y; Ayano M; Kimoto Y; Mitoma H; Kikukawa M; Akahoshi M; Arinobu Y; Horiuchi T; Akashi K; Niiro H
Clin Exp Immunol; 2020 Sep; 201(3):233-243. PubMed ID: 32538493
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity in vitro in chronic myelogenous leukaemia revealed after treating peripheral cells with cytosine arabinoside.
Pawelec G; Schmidt H; Rehbein A; Busch F
Cancer Immunol Immunother; 1989; 29(4):242-6. PubMed ID: 2526681
[TBL] [Abstract][Full Text] [Related]
15. Cellular immune responses to autologous chronic myelogenous leukaemia cells in vitro.
Pawelec G; Rehbein A; Schlotz E; da Silva P
Cancer Immunol Immunother; 1996 Mar; 42(3):193-9. PubMed ID: 8640848
[TBL] [Abstract][Full Text] [Related]
16. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.
Molldrem JJ; Lee PP; Kant S; Wieder E; Jiang W; Lu S; Wang C; Davis MM
J Clin Invest; 2003 Mar; 111(5):639-47. PubMed ID: 12618518
[TBL] [Abstract][Full Text] [Related]
17. Efficient generation of antileukemic autologous T cells by short-term culture and gamma-irradiation of myeloid leukemic cells.
Vereecque R; Saudemont A; Depil S; Corm S; Andrieux J; Soenen-Cornu V; Quesnel B
Cancer Immunol Immunother; 2004 Sep; 53(9):793-8. PubMed ID: 15098140
[TBL] [Abstract][Full Text] [Related]
18. CD54 is a surrogate marker of antigen presenting cell activation.
Sheikh NA; Jones LA
Cancer Immunol Immunother; 2008 Sep; 57(9):1381-90. PubMed ID: 18297282
[TBL] [Abstract][Full Text] [Related]
19. Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable?
Riley CL; Mathieu MG; Clark RE; McArdle SE; Rees RC
Cancer Immunol Immunother; 2009 Sep; 58(9):1489-99. PubMed ID: 19259670
[TBL] [Abstract][Full Text] [Related]
20. IFN-alpha regulates IL 10 production by CML cells in vitro.
Pawelec G; Schlotz E; Rehbein A
Cancer Immunol Immunother; 1999 Nov; 48(8):430-4. PubMed ID: 10550547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
